Cargando…
Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes
SIMPLE SUMMARY: This study focuses on understanding the real-world impact of newly introduced genetic tests and immune-based approaches on the survival of patients with non-small-cell lung cancer (NSCLC). Conducted in multiple medical centers in Japan, this study involved 863 patients and evaluated...
Autores principales: | Kobayashi, Nobuaki, Miura, Kenji, Kaneko, Ayami, Matsumoto, Hiromi, Somekawa, Kohei, Hirose, Tomofumi, Kajita, Yukihito, Tanaka, Anna, Teranishi, Shuhei, Sairenji, Yu, Kawashima, Hidetoshi, Yumoto, Kentaro, Tsukahara, Toshinori, Fukuda, Nobuhiko, Nishihira, Ryuichi, Kudo, Makoto, Miyazawa, Naoki, Kaneko, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648983/ https://www.ncbi.nlm.nih.gov/pubmed/37958421 http://dx.doi.org/10.3390/cancers15215248 |
Ejemplares similares
-
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021) -
Comparison of the slow‐pull and aspiration methods of endobronchial ultrasound‐guided transbronchial needle aspiration for next‐generation sequencing‐compatible tissue collection in non‐small cell lung cancer
por: Kajita, Yukihito, et al.
Publicado: (2023) -
Best regimens for treating chemo‐naïve incurable squamous non‐small cell lung cancer with a programmed death‐ligand 1 tumor proportion score of 1%–49%: A network meta‐analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021) -
Retrospective analysis of independent predictors of progression‐free survival in patients with
EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib
por: Teranishi, Shuhei, et al.
Publicado: (2022) -
The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)